The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Neonatal Immunization With Pneumococcal Conjugate Vaccine In Papua New Guinea
Funder
National Health and Medical Research Council
Funding Amount
$1,181,966.00
Summary
One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the dev ....One million children die every year of pneumococcal (Pnc) disease, the majority in the third world. Many die in early infancy and babies may benefit from immunisation with a Pnc conjugate vaccine (PrevenarTM) at birth. The Papua New Guinea (PNG) Insatiate of Medical Research; Telethon Institute for Child Health Research and the Department of Paediatrics, University of Western Australia, will collaborate to closely examine the safety of this approach, particularly with regard to impact on the development of immunity and response to other vaccines given to infants. This study will also provide a unique opportunity for training of PNG and Australian scientists in both countries; transfer state-of-the-art immunological technology and stimulate further collaborations on respiratory infections in the region.Read moreRead less
Australia-Europe Malaria Research Cooperation - OzEMalaR
Funder
National Health and Medical Research Council
Funding Amount
$859,731.00
Summary
EVIMalaR is a European Virtual Institute for Malaria Research that combines 42 of the European Union’s leading malaria research groups plus 4 Africans, 1 Indian institution, and 1 Australian. EVIMalaR faculty will combine expertise to produce a Network of Excellence that enhances and harmonises experimental approaches through shared technological platforms, exchange visits, shared PhD students, shared resources such as databases, reagent banks and protocols across pathology, infection, immunolog ....EVIMalaR is a European Virtual Institute for Malaria Research that combines 42 of the European Union’s leading malaria research groups plus 4 Africans, 1 Indian institution, and 1 Australian. EVIMalaR faculty will combine expertise to produce a Network of Excellence that enhances and harmonises experimental approaches through shared technological platforms, exchange visits, shared PhD students, shared resources such as databases, reagent banks and protocols across pathology, infection, immunology and biochemistry. Malaria is a global problem with no single solution. A large, but sometimes disjointed, research community is addressing the problem, but more collaboration is vital. OzEMalaR will link 34 Australian labs with 47 European, African and Indian malaria researchers. Funding will enable exchange of modern technologies by supporting early career researchers (PhD and postdocs) from Australia to work and be trained in top European labs. European trainees will work and be trained by Australian malariologists using reciprocal EU supportRead moreRead less
Are Routine Healthcare Worker Hand Hygiene Protocols (soap/water, Alcohol-based Handrub) Effective Against Influenza?
Funder
National Health and Medical Research Council
Funding Amount
$99,950.00
Summary
Although influenza is mainly spread from person-to-person by aerosol transmission (coughing, sneezing etc), there is growing evidence that spread also occurs on the hands of infected patients and their carers (non-aerosol transmission). Because of this, health authorities now recommend the use of careful hand hygiene (HH: hand washing with soap-water or use of alcohol-based hand rub solutions [ABHRS]) by healthcare workers (HCWs) and patients. However, despite these recommendations, there are no ....Although influenza is mainly spread from person-to-person by aerosol transmission (coughing, sneezing etc), there is growing evidence that spread also occurs on the hands of infected patients and their carers (non-aerosol transmission). Because of this, health authorities now recommend the use of careful hand hygiene (HH: hand washing with soap-water or use of alcohol-based hand rub solutions [ABHRS]) by healthcare workers (HCWs) and patients. However, despite these recommendations, there are no data that demonstrate the effectiveness of such HH protocols. This project aims to assess the clinical effectiveness of four HH protocols (handwashing with soap-water, alcohol-only ABHRS, two alcohol-chlorhexidine ABHRS) in common use in Australian hospitals to see which protocol is best for killing influenza virus. We also plan to assess how long influenza virus remains infectious on HCWs hands if they fail to use appropriate HH. Since it could be dangerous to use live avian influenza virus in this study, we plan to use the H1N1 influenza A strain that was a component of the influenza vaccine administered to most HCWs in 2005. Thus, only HCWs with protective immunity to H1N1 will participate in a series of tests in which they will have their hands artificially contaminated with a known concentration of live H1N1 before using either no HH, or one of the four HH protocols, followed by an assessment (virus culture and molecular tests) or the amount of H1N1 surviving on their hands after each protocol. Some selected HCWs will also have the amount of surviving virus assessed 30 and 60 minutes after contamination to identify how long H1N1 survives on HCWs hands should they not use appropriate HH. Following all protocols, all HCWs will perform a detailed surgical scrub (similar to surgeons before an operation) to make certain that all H1N1 is killed to avoid any infection of themselves or their contacts. The study will be undertaken in special, secure, negative-pressure rooms at Austin Hospital away from patient care areas to provide maximum safety conditions. All virus culture and molecular tests will be performed in the virus Identification Laboratory at the Victorian Infectious Disease Reference Laboratory (VIDRL), Melbourne. Results of the study should help identify which HH protocol provides the most protection against influenza.Read moreRead less
Safety Of Hendra Virus Anti-G Glycoprotein Monoclonal Antibody In Humans
Funder
National Health and Medical Research Council
Funding Amount
$400,000.00
Summary
Hendra virus infection in humans is a serious, and often fatal, disease. No cure exists for Hendra infection and existing treatments are ineffective. Recently, a human monoclonal antibody has shown great promise in protecting animals from developing the disease. This project aims to perform preclinical safety testing and a Phase I clinical trial to establish the safety profile of this antibody such that it can be used to prevent Hendra infection in humans exposed to the disease.
Establishing The Capacity For H5N1 Challenge Of Ferrets Within Australia &optimizing Pandemic Vaccines In This Model
Funder
National Health and Medical Research Council
Funding Amount
$405,513.00
Summary
Australia is currently in the process of manufacturing vaccines for use in people against strains of avian influenza viruses circulating in South East Asia as part of a national preparedness program for an influenza pandemic. These particular avian flu viruses are capable of causing severe disease and death in humans as well as birds, although at present they are not highly transmissible between people. Should the avian influenza viruses mutate to gain this capability, it will be necessary to in ....Australia is currently in the process of manufacturing vaccines for use in people against strains of avian influenza viruses circulating in South East Asia as part of a national preparedness program for an influenza pandemic. These particular avian flu viruses are capable of causing severe disease and death in humans as well as birds, although at present they are not highly transmissible between people. Should the avian influenza viruses mutate to gain this capability, it will be necessary to institute widespread vaccination of the Australian population. It is not possible to test the vaccines in people for their effectiveness against avian influenza infection prior to a disease outbreak, so an animal model for the disease will be used to assist in optimizing the formulation of flu vaccines and in testing their efficacy in preventing infection or reducing the severity of disease. Ferrets are natural hosts for flu viruses, have similar responses to vaccination as people, and develop a similar disease to humans when infected with influenza. These animals will be used to assist vaccine manufacturers in providing the best type of vaccine for protection of Australians in the face of a global flu pandemic.Read moreRead less
Avian Influenza: Molecular Basis Of Potential Resistance To Neuraminidase Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$87,250.00
Summary
In this project we will visualize an avian flu protein bound to various antiviral drugs that are currently in the clinic (Relenza and Tamiflu) or are in clinical development. In the immediate term, the images derived from the project will be a valuable predictive tool for evaluating the likely effectiveness of antiviral drugs and vaccines in response to emerging viral resistance. In the longer term the images could be used to guide the development of new antivirals and vaccines against avian flu ....In this project we will visualize an avian flu protein bound to various antiviral drugs that are currently in the clinic (Relenza and Tamiflu) or are in clinical development. In the immediate term, the images derived from the project will be a valuable predictive tool for evaluating the likely effectiveness of antiviral drugs and vaccines in response to emerging viral resistance. In the longer term the images could be used to guide the development of new antivirals and vaccines against avian flu. This initiative brings together Industry leaders in the development of influenza antivirals and vaccines, CSL and Biota, with a leading Medical Research Institute.Read moreRead less
Production Of Nasal Filters: Enhanced Prophylactic Protection From Aerosol Exposure
Funder
National Health and Medical Research Council
Funding Amount
$147,000.00
Summary
Influenza is a highly contagious disease that is transmitted via infective secretions containing the virus. An infected person produces tiny droplets of these secretions when coughing, sneezing, and talking, and the droplets are disseminated into the air where they are subsequently inhaled by others. A common way of preventing such transmission is to wear a mask to prevent droplet inhalation. While such masks may greatly reduce exposure, they do not eliminate it, as some viruses can pass around ....Influenza is a highly contagious disease that is transmitted via infective secretions containing the virus. An infected person produces tiny droplets of these secretions when coughing, sneezing, and talking, and the droplets are disseminated into the air where they are subsequently inhaled by others. A common way of preventing such transmission is to wear a mask to prevent droplet inhalation. While such masks may greatly reduce exposure, they do not eliminate it, as some viruses can pass around the edges of masks, particularly if it fits poorly, and also a small percentage can pass through the filter material. While influenza is usually not a major health problem in the general community, the emergence of a more hazardous strain will place an additional burden on health care and other facilities, and requires the development and optimization of measures to minimize virus spread and protect those who are exposed. The aim of this project is to build small filters that can be worn in the nose to provide additional filtration of inhaled air. These filters would be worn in combination with a mask in high exposure circumstances, such as by health care workers when treating infected patients or could be used when a mask was not normally worn to provide effective and discreet protection, such as in crowded public places. Developing such filters builds on our experience of making small samplers worn in the nose to measure allergen exposure. This experience is combined with advanced filter materials developed by leading US researchers that permit the efficient filtration of particles as small as viruses. This project will be conducted in collaboration with a leading Australian design group, and we will design and evaluate such filters for their ability to capture virus and thus protect the wearer. The filters should provide an intuitive, effective and inexpensive method to be used in combination with other hygiene measures to increase personal protection from acquiring highly transmissible respiratory diseases, particularly influenza. We expect to have prototypes of the filters available in 6 months so that production can commence.Read moreRead less
Surveillance And Analysis Of Avian Influenza Viruses In Wild Birds In Australia
Funder
National Health and Medical Research Council
Funding Amount
$250,237.00
Summary
Birds are commonly infected with bird flu viruses but most of these viruses do not cause disease. However, certain types of bird flu viruses, such as the H5N1 strain, can cause severe illness and death in 100% of infected birds. There is currently an epidemic of H5N1 bird flu occurring in Asia. Occasionally humans become infected by bird to human transmission and since 2003, 130+ people have been infected with H5N1 resulting in 60+ deaths. There are 3 ways in which dangerous strains of the virus ....Birds are commonly infected with bird flu viruses but most of these viruses do not cause disease. However, certain types of bird flu viruses, such as the H5N1 strain, can cause severe illness and death in 100% of infected birds. There is currently an epidemic of H5N1 bird flu occurring in Asia. Occasionally humans become infected by bird to human transmission and since 2003, 130+ people have been infected with H5N1 resulting in 60+ deaths. There are 3 ways in which dangerous strains of the virus may be brought to Australia by; infected people, domestic birds and migratory wading birds. In order to monitor the import of these viruses by migratory birds we will catch and take samples from large numbers of these birds in important areas where they congregate close to humans and poultry farms. We will identify what types of bird flu viruses these birds are carrying and if the viruses are capable of causing disease in birds and humans. We will also see if they can be treated by the influenza drugs that we currently have and we will study these viruses to find new drug targets. These viruses are commonest in ducks. Migratory wading birds and local ducks live in the same habitats so there is the chance that the wading birds and ducks could pass the viruses to each other. There is an additional concern that non-disease causing viruses could mutate in ducks and become pathogenic and pass from bird to bird or even human to human transmission which could cause a major human epidemic of bird flu in Australia. So we will also take samples from local ducks that occur in the same areas as the wading birds and test them for viruses as well. Our results will show what kinds of viruses are being carried by wading birds and ducks and if these viruses are a danger to people and poultry. We can then manage important areas so that humans and poultry do not come into contact with these viruses.Read moreRead less
A Prospective Study To Examine The Effectiveness And Safety Of Antivirals Against Pandemic Influenza
Funder
National Health and Medical Research Council
Funding Amount
$142,394.00
Summary
Pandemic influenza could cause significant mortality in populations of Australia and the south-east Asian region. Currently, avian influenza A (H5N1) is a concern to public health agencies because of its extreme pathogenicity. At present this strain is not transmitted readily between humans. A number of drugs are available to treat influenza infection in humans and research has shown these to be effective in preventing significant mortality in the setting of seasonal influenza epidemics (specifi ....Pandemic influenza could cause significant mortality in populations of Australia and the south-east Asian region. Currently, avian influenza A (H5N1) is a concern to public health agencies because of its extreme pathogenicity. At present this strain is not transmitted readily between humans. A number of drugs are available to treat influenza infection in humans and research has shown these to be effective in preventing significant mortality in the setting of seasonal influenza epidemics (specifically the influenza neuraminidase inhibitors _NIs). As a consequence public health agencies around the world have been stockpiling these drugs and developing sophisticated plans for their use if an influenza pandemic was announced. However, there are no data indicating that the neuraminidase inhibitors (NIs) are safe and effective when used to manage pandemic influenza. Neither are there any data to support the use of these drugs on a population basis. Genetic resistance to NIS has been described but it is not clear if this has any relevance to public health. Our research will clarify this issue. This project will develop a number of clinical trials that could be implemented rapidly should pandemic influenza ever be announced by health authorities in Australia-Singapore or Hong Kong. Patients with suspected influenza infection will be asked to provide informed consent prior to commencing NI therapy. Clinical information will then be collected for a period of approximately one month along with some blood samples and swabs from the throat and nasal passages. Data will be analysed as quickly as possible to help inform the continued use of NI therapy as a cornerstone of the public health agency response to pandemic influenza. In addition, the study team will prepare clinical trials to be conducted in essential workers who are likely to receive long-term NI preventive treatment as well as the immediate contacts of people with presumed influenza infection who are likely to receive short-term prophylaxis with NIs.Read moreRead less
Mucosal Vaccine For Influenza On Inactivated Virus And Mannan
Funder
National Health and Medical Research Council
Funding Amount
$131,993.00
Summary
Influenza is a respiratory disease that causes significant morbidity and mortality worldwide. Current influenza vaccines are a preparation of three currently circulating inactivated influenza strains that induces an antibody response that can combat the virus and therefore infection. Despite the availability of a vaccine new approaches are needed to increase the activity, usage and distribution. To this end several approaches based on using additional agents to increase the immunogenicity and ne ....Influenza is a respiratory disease that causes significant morbidity and mortality worldwide. Current influenza vaccines are a preparation of three currently circulating inactivated influenza strains that induces an antibody response that can combat the virus and therefore infection. Despite the availability of a vaccine new approaches are needed to increase the activity, usage and distribution. To this end several approaches based on using additional agents to increase the immunogenicity and needle free delivery are being explored. We have a natural sugar based compound that can be used to increase the body's immunity to cancers and infectious agents such as bacteria and viruses. When these preparations are applied into the nostril of mice they generate antibody responses to the infectious agent in the lungs, gut, tears, saliva that can act as a barrier to infectious agents. We are incorporating an inactive flu virus with this natural sugar to investigate if it produces antibody that can protect mice and ferrets from the flu virus. This method will be first tried with the human flu virus and if successful will be tried with the bird flu virus. If the preparation can protect mice and ferrets from human or bird flu infection it could develop into a human vaccine against bird flu. Since it can be administered by the nose it will be widely used and can be used readily without qualified personnel in the case of a pandemic.Read moreRead less